A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Summary

This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy. Safety, efficacy and tolerability of BBI503 will be assessed for the duration of study treatment.

Timeline

Start

2015-02

Primary completion

2017-12-14

Completion

2017-12-14

Drugs

Indications